Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas

Cancer

Volumn 97, Issue 11, 2003, Pages 2848-2852

  Patel, Shreyaskumar R ^a   Beach, Jennifer ^a   Papadopoulos, Nicholas ^a   Burgess, M Andrew ^a   Trent, Jonathan ^a   Jenkins, Jan ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

9 nitrocamptothecin; Gastrointestinal stromal tumors; Rubitecan; Soft tissue sarcomas

Indexed keywords

RUBITECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 0037507379     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11385     Document Type: Article

References (12)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2002;52:23-47.
2. Patel SR, Legha SS, Salem PA, et al. Evaluation of ifosfamide in metastatic leiomyosarcomas of GI origin [abstract]. Proc Am Soc Clin Oncol. 1991;31:352.
3. Patel SR, Chu P, Vadhan-Raj S, et al. Differential responsiveness of leiomyosarcoma (leio) arising at different sites to doxorubicin-based chemotherapy [abstract]. Proc Am Assoc Cancer Res. 1997;38:325.
4. Patel SR. Dose-intensive chemotherapy for soft-tissue sarcomas. In: Perry MC, editor. American Society of Clinical Oncology educational booklet (Spring 2000). Baltimore: Lippincott-Williams and Wilkins, 2000:453-457.
5. Patel SR. New agents in the treatment of soft-tissue sarcomas. Expert Opin Investig Drugs. 2000;9:1545-1551.
6. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1996;88:3888-3890.
7. Hsiang Y-H, Libou MG, Liu LF. Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077-5082.
8. Kharbanda S, Ruin E, Gunji H, et al. Camptothecin and its derivatives induce expression of the c-jun proto-oncogene in human myeloid leukemia cells. Cancer Res. 1991;51:6636-6642.
9. Natelson E, Giovanella BC, Veschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 9-nitro-20-(S)-camptothecin as anticancer agents. Ann NY Acad Sci. 1996;803:224-230.
10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
11. Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463-3469.
12. Mace JR, Chandler W, Paulino A, et al. Response of chordoma to a protracted schedule of 9-NC: an update [abstract]. Proc Am Soc Clin Oncol. 2002;21:407a.